Evidence map›Paper›PMID 22944627›Full record

ArticleVaccine2012

HLA-DR specific monoclonal antibodies block lymphoproliferative response to measles vaccine in vitro: a pilot study.

David M Phelan, Gregory A Poland

Abstract read
In one paragraph

Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

David M PhelanMayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA.
Gregory A Poland
Mayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

The Immunogenetics of Measles ImmunityR01AI033144 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 1993 to 2022
$8.1M
Immunogenetic Mechanisms of Vaccine ResponseR37AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2011 to 2020
$5.4M
IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSER01AI048793 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2001 to 2010
$4.3M
NIAID NIH HHS AI 33144NIAID NIH HHS AI 48793NIAID NIH HHS R01 AI033144NIAID NIH HHS R01 AI048793NIAID NIH HHS R37 AI048793
6 · The paper itself

Abstract

Humoral and cell-mediated immune responses are important in protection against measles. Non-response to vaccination has been associated with specific HLA-DR and HLA-DQ alleles; however, little is known about the relative importance of these alleles in the cellular immune response induced by measles virus vaccine. To investigate the role of HLA-DR/DQ class II restriction, a small pilot study was conducted. Lymphoproliferation assays using class II DR and DQ-specific monoclonal antibodies (MoAb) were performed at one week and two weeks post immunization with MMRII vaccine. The mean stimulation index (SI) was 4.4 and 5.3 at one and two weeks with reductions in SI of 47.6% and 70.2%, respectively, following the addition of DR-specific MoAb (p<0.001). These results clearly show that a significant proportion of the cell-mediated immune response to measles virus vaccine, as measured by SI, is HLA-DR restricted.

Indexed as

Immunity, CellularAdultAntibodies, MonoclonalCell ProliferationHLA-DQ AntigensHLA-DR AntigensHumansLeukocytes, MononuclearMeasles-Mumps-Rubella VaccineMeasles VaccinePilot ProjectsAntibodies, MonoclonalHLA-DQ AntigensHLA-DR AntigensMeasles-Mumps-Rubella VaccineMeasles Vaccine

Identifiers

PMID22944627
PMCPMC3473139
OpenAlexW1970586653

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.